2-HOBA Phase 2 Clinical Trial in Rheumatoid Arthritis
Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This is a phase 2 study to determine 2-HOBA's tolerability, safety, and effect on
isoLG-adducts in patients with rheumatoid arthritis (RA) patients. Up to 32 subjects will be
randomized to 750mg 2-HOBA or matching placebo three times a day for 4 weeks.
As primary outcome measures we will compare tolerability and adverse events and changes in
isoLG adducts in active and placebo arms. Among prespecified exploratory outcomes we will
compare changes in markers of inflammation, DAS28 score, and 24-hour blood pressure in active
and placebo arms. This pilot study will inform the feasibility and design of future studies
to examine the efficacy of 2-HOBA in RA patients.